{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:36Z","timestamp":1792602936853,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jaip.2020.09.021","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:12:37Z","timestamp":1601298757000},"page":"819-829.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":219,"title":["Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"9","author":[{"given":"Roger J.","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Krantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Cosby A.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.09.021_bib1","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jaip.2019.11.035","article-title":"Adverse reactions associated with penicillins, carbapenems, monobactams, and clindamycin: a retrospective population-based study","volume":"8","author":"Liang","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)\u2014classification, diagnosis and management: review of the EAACI\/ENDA(#) and GA2LEN\/HANNA\u2217","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.09.021_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaip.2019.09.038","article-title":"MRGPRX2 signaling and skin test results","volume":"8","author":"Kelso","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib4","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jaip.2019.02.015","article-title":"Mastocytosis, quinolones, MRGPRX2, and anaphylaxis","volume":"7","author":"Weiler","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jaip.2020.09.021_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2146\/ajhp130571","article-title":"Investigation of pegloticase-associated adverse events from a nationwide reporting system database","volume":"71","author":"Gentry","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2020.09.021_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740338.2013.832752","article-title":"Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature","volume":"13","author":"Raisch","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2020.09.021_bib9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.jaip.2019.12.041","article-title":"Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy","volume":"8","author":"Krantz","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1756-9966-30-93","article-title":"Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS","volume":"30","author":"Kadoyama","year":"2011","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.jaip.2020.09.021_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1517\/14740338.2011.582865","article-title":"Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication","volume":"10","author":"Raisch","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2020.09.021_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2008.10.049","article-title":"Anaphylaxis fatalities and admissions in Australia","volume":"123","author":"Liew","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaip.2018.06.010","article-title":"Drug-induced anaphylaxis documented in electronic health records","volume":"7","author":"Dhopeshwarkar","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib16","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib17","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.10.029","article-title":"Case fatality and population mortality associated with anaphylaxis in the United States","volume":"133","author":"Ma","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/ACI.0000000000000305","article-title":"Epidemiology of severe anaphylaxis: can we use population-based data to understand anaphylaxis?","volume":"16","author":"Turner","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib20","doi-asserted-by":"crossref","first-page":"e14114","DOI":"10.1097\/MD.0000000000014114","article-title":"Common causes of emergency department visits for anaphylaxis in Korean community hospitals: a cross-sectional study","volume":"98","author":"Cho","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaip.2020.09.021_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s11096-017-0535-2","article-title":"Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database","volume":"40","author":"Zhao","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.jaip.2020.09.021_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jdermsci.2008.04.002","article-title":"Sex hormones and urticaria","volume":"52","author":"Kasperska-Zajac","year":"2008","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2020.09.021_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2020.09.021_bib24","first-page":"383","article-title":"Recurrence of anaphylaxis in a Spanish series","volume":"23","author":"Alonso","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1710-1492-10-38","article-title":"Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011","volume":"10","author":"Xu","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2014.10.021","article-title":"Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012","volume":"135","author":"Turner","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib27","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/cea.12748","article-title":"Increases in anaphylaxis fatalities in Australia from 1997 to 2013","volume":"46","author":"Mullins","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.09.021_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaip.2014.11.002","article-title":"Improving the effectiveness of penicillin allergy de-labeling","volume":"3","author":"Bourke","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-141-1-200407060-00010","article-title":"Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins","volume":"141","author":"Romano","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2020.09.021_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaci.2016.01.025","article-title":"Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a T cell-mediated hypersensitivity to penicillins","volume":"138","author":"Romano","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaci.2015.03.012","article-title":"IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins","volume":"136","author":"Romano","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jaip.2017.07.033","article-title":"Are cephalosporins safe for use in penicillin allergy without prior allergy evaluation?","volume":"6","author":"Macy","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2165\/00002018-200629110-00008","article-title":"Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use","volume":"29","author":"Sachs","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaip.2020.09.021_bib34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/ACI.0000000000000550","article-title":"Biologics and anaphylaxis","volume":"19","author":"Sala-Cunill","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib35","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2020.09.021_bib37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jaip.2017.04.044","article-title":"First-dose anaphylaxis to infliximab: a case of mammalian meat allergy","volume":"5","author":"Chitnavis","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.09.021_bib38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1046\/j.1365-2222.2000.00864.x","article-title":"Lessons for management of anaphylaxis from a study of fatal reactions","volume":"30","author":"Pumphrey","year":"2000","journal-title":"Clin Exp Allergy"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820309995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820309995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:27:26Z","timestamp":1761974846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820309995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2213219820309995"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}